Jiangsu Baoli International Investment (300135.SZ) controlling shareholder is still in talks regarding the transfer of shares. Trading will remain suspended starting from November 18.
Bo Li International (300135.SZ) issued an announcement that the company's controlling shareholder and actual controller, Zhou Dehong, and his concerted acting...
Jiangsu Baoli International Investment (300135.SZ) announced that its controlling shareholder and actual controller Zhou Dehong, along with his concerted action person Zhou Xiufeng, are planning significant matters that may result in a change in the company's controlling rights. In order to ensure fair disclosure of information, protect the interests of investors, and avoid causing abnormal fluctuations in the company's stock price, the company's stock will continue to be suspended from trading starting from November 18, 2024 (Monday), with the expected suspension not exceeding 1 trading day. As of the date of this announcement, the parties involved in the transaction have been discussing the equity transfer plan. As of now, the matter is still under discussion, and the parties involved have not yet signed an agreement.
Related Articles

CHINFMINING(01258): Regarding the tailings dam incident, Qianbi Xi wet method has already fully fulfilled the repair and governance obligations in accordance with government instructions.

A-share hot topics in the evening | NVIDIA invests $5 billion in Intel

Energizer Medicine-B (02595): Hong Kong public offering oversubscribed by 2662.79 times, net proceeds from global offering approximately 1.67 billion Hong Kong dollars.
CHINFMINING(01258): Regarding the tailings dam incident, Qianbi Xi wet method has already fully fulfilled the repair and governance obligations in accordance with government instructions.

A-share hot topics in the evening | NVIDIA invests $5 billion in Intel

Energizer Medicine-B (02595): Hong Kong public offering oversubscribed by 2662.79 times, net proceeds from global offering approximately 1.67 billion Hong Kong dollars.

RECOMMEND

Three-Year R&D Spend Drains RMB 2.4 Billion, Urgent Cash Needs Drive Maiwei Biotech Back to Hong Kong Amid Compliance Scrutiny
18/09/2025

Why Generating Profit Remains Challenging for Lidar Companies
18/09/2025

SEC Adopts Landmark Rule to Restrict Shareholder Class Actions in Bid to Revive IPO Market
18/09/2025